EN | RU
EN | RU

Help Support

Back

Study determines long-term effects of Teriparatide treatment in severe osteoporosis

fracture prevalence fracture prevalence
fracture prevalence fracture prevalence

What's new?

At 10 years of follow-up, anabolic hormonal therapy with Teriparatide decreased fracture prevalence to levels equivalent to those in the general population.

According to the findings of a controlled 10-year follow-up research, fracture rate reduced from 100 to 35% in all osteoporosis-affected people who had been treated with Teriparatide for a mean period of 18 months followed by other bone-specific treatment during a 10-year follow-up. Investigators compared people with osteoporosis to placebo-treated osteoporosis people and the general population to assess the long-term impact of subcutaneous Teriparatide on fractures and health-related quality of life.

A total of 40 women (mean age 69 years) suffering from osteoporosis and spinal compression received Teriparatide 20 μg every day for a mean of eighteen months. From a placebo-controlled, randomized, double-blind, growth hormone trial, placebo-treated women with osteoporosis (n = 25, mean age = 60 years) with daily subcutaneous injections for eighteen months were employed as the control group. Dual-energy x-ray absorptiometry was used together with questionnaires at the beginning, 18 months, 36 months, and 10 years thereafter.

Overall, 233 women of a comparable age who were chosen at random from the population served as controls and were followed concurrently. Every fracture was confirmed through an X-ray. Reduction in fractures was reported from 100 to 35% in the teriparatide users to similar levels as in the population sample, 25 to 28% at baseline and following ten years, respectively.

Teriparatide caused a rise in bone mineral density, which, after 10 years, recovered to its pre-treatment values. The Teriparatide group had a poorer health-related quality of life than the general population before, and after therapy, as well as at 10 years. In osteoporosis-affected people, health associated quality of life was low and not affected by bone-specific therapy.

Teriparatide was well-tolerated and efficient with improvement in bone mass in lumbar spine and femoral neck. In severely affected people, it did not enhance health-related quality of life. Teriparatide is suggested as the first-line therapy in secondary prophylaxis of osteoporosis.

Source:

BMC Musculoskeletal Disorder

Article:

Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study

Authors:

Georgios Kontogeorgos et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: